Value gained By Xeris Biopharma Holdings Inc. (XERS) In The Past Week: $1.3400

0
74

Xeris Biopharma Holdings Inc. (NASDAQ:XERS) finished Friday with an addition of $0.08 to close at $1.33, an upside of 6.40 percent. An average of 686,140 shares of common stock have been traded in the last five days. There was a gain of $0.0700 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 515,090 shares traded, while the 50-day average volume stands at 631,962.

XERS stock has decreased by -11.33% in the last month. The company shares reached their 1-month lowest point of $1.1400 on 12/28/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $1.14 and a high of $3.17 in 52 weeks. It has reached a new high 1 time so far this year and lost -54.61% or -$1.6000 in price. In spite of this, the price is down -58.03% from the 52-week high.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Insider Transactions

XERS stock investors should be aware that Xeris Biopharma Holdings Inc. (XERS) stock had its last reported insider trading activity 312 days ago on Dec 13.

Valuation Metrics

Xeris Biopharma Holdings Inc. (XERS) stock’s beta is 1.39. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1.84, the price-to-book (PB) ratio at 3.33.

Financial Health

The quick ratio of Xeris Biopharma Holdings Inc. for the three months ended June 29 was 1.90, and the current ratio was 2.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 2.52 and a total debt to equity ratio of 2.52 for the quarter ending June 29. Its gross profit as reported stood at $36.27 million compared to revenue of $49.59 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Xeris Biopharma Holdings Inc.’s return on assets was -41.90%.

Earnings Surprise

For the three-month period that ended June 29, Xeris Biopharma Holdings Inc. had $9.32 million in cash and short-term investments compared to $138.51 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$21.83 million in the quarter, while revenues of -$26.19 million were shrunk -19.15%. The analyst consensus anticipated Xeris Biopharma Holdings Inc.’s latest quarter earnings to come in at -$0.23 per share, but it turned out to be -$0.19, a 17.40% surprise. For the quarter, EBITDA amounted to -$15.27 million. Shareholders own equity worth $135.99 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Xeris Biopharma Holdings Inc. (XERS) price momentum. RSI 9-day as of the close on 30 December was 53.39%, suggesting the stock is Neutral, with historical volatility in this time frame at 74.63%.

As of today, XERS’s price is $1.2300 +5.56% or $0.0700 from its 5-day moving average. XERS is currently trading -14.19% lower than its 20-day SMA and -21.76% lower than its 100-day SMA. However, the stock’s current price level is +8.13% above the SMA50 and -52.33% below the SMA200.

The stochastic %K and %D were 30.28% and 17.06%, respectively, and the average true range (ATR) was 0.0826. With the 14-day stochastic at 54.58% and the average true range at 0.0812, the RSI (14) stands at 49.29%. The stock has reached -0.0111 on the 9-day MACD Oscillator while the 14-day reading was at -0.0507.

Analyst Ratings

Jefferies launched coverage on Xeris Biopharma Holdings Inc. (NASDAQ: XERS) in its analyst report released on October 21, 2022. The firm assigned the stock a Buy rating. The consensus rating for Xeris Biopharma Holdings Inc. (XERS) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell XERS, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.

What is XERS’s price target for the next 12 months?

Analysts predict a range of price targets between $4.00 and $6.00, with a median target of $5.50. Taking a look at these predictions, the average price target given by analysts for Xeris Biopharma Holdings Inc. (XERS) stock is $5.25.

LEAVE A REPLY

Please enter your comment!
Please enter your name here